AKERO THERAPEUTICS INC's ticker is AKRO and the CUSIP is 00973Y108. A total of 99 filers reported holding AKERO THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,830,996 | +702.9% | 36,200 | +641.2% | 0.00% | – |
| Q2 2023 | $228,034 | +7335.1% | 4,884 | -93.9% | 0.00% | -100.0% |
| Q1 2023 | $3,067 | -77.3% | 80,166 | -67.5% | 0.00% | -71.4% |
| Q4 2022 | $13,537 | -99.7% | 247,017 | -52.6% | 0.01% | +133.3% |
| Q2 2022 | $4,921,000 | +431.4% | 520,769 | +698.2% | 0.00% | – |
| Q1 2022 | $926,000 | +121.5% | 65,244 | +230.5% | 0.00% | – |
| Q4 2021 | $418,000 | -86.7% | 19,743 | -81.7% | 0.00% | -100.0% |
| Q1 2021 | $3,133,000 | -54.1% | 107,992 | -59.2% | 0.00% | -60.0% |
| Q4 2020 | $6,822,000 | +41.7% | 264,411 | +69.2% | 0.01% | -16.7% |
| Q3 2020 | $4,813,000 | +49.1% | 156,314 | +20.6% | 0.01% | +50.0% |
| Q2 2020 | $3,229,000 | +136.0% | 129,565 | +100.8% | 0.00% | +33.3% |
| Q1 2020 | $1,368,000 | -18.3% | 64,539 | -12.3% | 0.00% | 0.0% |
| Q3 2019 | $1,674,000 | -47.9% | 73,621 | -56.1% | 0.00% | -40.0% |
| Q2 2019 | $3,212,000 | – | 167,746 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Skorpios Trust | 3,271,829 | $179,296 | 57.03% |
| Redmile Group, LLC | 2,632,912 | $144,283,578 | 5.90% |
| Avidity Partners Management LP | 3,825,000 | $209,610,000 | 4.54% |
| COMMODORE CAPITAL LP | 537,076 | $29,432 | 4.44% |
| Atlas Venture Life Science Advisors, LLC | 594,251 | $32,564,955 | 3.92% |
| Paradigm Biocapital Advisors LP | 604,544 | $33,129,011 | 3.89% |
| Yiheng Capital Management, L.P. | 1,468,905 | $80,495,994 | 3.56% |
| Altium Capital Management LP | 125,000 | $6,850,000 | 3.48% |
| Tri Locum Partners LP | 128,851 | $7,061,000 | 2.86% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 172,100 | $9,431,080 | 2.70% |